Metraipolis › archive › dc_024b1191ac16

Edoxaban versus Apixaban Outcomes Differences in 8,444 Patients with Atrial Fibrillation from Italy: A Real-World Use Comparison — Europe PMC PMID:42368625

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42368625
DOI
10.1055/a-2822-9746
License (as archived)
solo-consultazione
Archived
2026-11-04T02:42:31.690Z
SHA-256 of the archived text
c1a910a19b051eabc87de5e45a9e9301d2dbf1819ed065582109810277d7c3e7
Stable URL of this page
https://metraipolis.com/documento/dc_024b1191ac16

How to cite

Edoxaban versus Apixaban Outcomes Differences in 8,444 Patients with Atrial Fibrillation from Italy: A Real-World Use Comparison — Europe PMC PMID:42368625 — Europe PMC (en), https://europepmc.org/article/MED/42368625 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_024b1191ac16 (Metraipolis archive dc_024b1191ac16, sha256 c1a910a19b051eabc87de5e45a9e9301d2dbf1819ed065582109810277d7c3e7)
BibTeX
@misc{dc024b1191ac16,
  title = {Edoxaban versus Apixaban Outcomes Differences in 8,444 Patients with Atrial Fibrillation from Italy: A Real-World Use Comparison — Europe PMC PMID:42368625},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42368625},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_024b1191ac16; sha256 c1a910a19b051eabc87de5e45a9e9301d2dbf1819ed065582109810277d7c3e7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42368625. Agents can read the archived copy with the MCP tool read_document.